PriceTargets.com logo

Daxor - DXR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 130.37%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.55 As of 06/8/2023 01:00 AM ET
▼ -0.04 (-0.42%)

This chart shows the closing price for DXR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daxor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXR

Analyst Price Target is $22.00
▲ +130.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Daxor in the last 3 months. The average price target is $22.00, with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 130.37% upside from the last price of $9.55.

This chart shows the closing price for DXR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Daxor.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/3/2023Maxim GroupReiterated RatingBuy$22.00
3/25/2021Ascendiant Capital MarketsReiterated RatingBuy$21.00
9/2/2020Maxim GroupReiterated RatingBuy$22.00
9/30/2019Roth CapitalReiterated RatingNeutral
9/30/2019Roth CapitalInitiated CoverageNeutral$18.00
7/29/2019Maxim GroupInitiated CoverageBuy$22.00
5/16/2019Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$20.00
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/10/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/9/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Daxor logo
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.
Read More

Today's Range

Now: $9.55
Low: $9.55
High: $9.63

50 Day Range

MA: N/A

52 Week Range

Now: $9.55
Low: $7.81
High: $14.55

Volume

4,189 shs

Average Volume

8,257 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daxor?

The following Wall Street analysts have issued stock ratings on Daxor in the last twelve months: Maxim Group, and TheStreet.
View the latest analyst ratings for DXR.

What is the current price target for Daxor?

1 Wall Street analysts have set twelve-month price targets for Daxor in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 130.4%. Maxim Group has the highest price target set, predicting DXR will reach $22.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $22.00 for Daxor in the next year.
View the latest price targets for DXR.

What is the current consensus analyst rating for Daxor?

Daxor currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXR will outperform the market and that investors should add to their positions of Daxor.
View the latest ratings for DXR.

What other companies compete with Daxor?

Other companies that are similar to Daxor include Adynxx, Calmare Therapeutics, Dex Liquidating, Endologix and LifePoint. Learn More about companies similar to Daxor.

How do I contact Daxor's investor relations team?

Daxor's physical mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company's listed phone number is (865) 425-0555 and its investor relations email address is [email protected]. The official website for Daxor is www.daxor.com. Learn More about contacing Daxor investor relations.